Kyverna Therapeutics Inc. Faces Stock Volatility Amid Biotech Challenges
Kyverna Therapeutics Inc. has experienced significant stock price volatility since its IPO, but remains committed to developing innovative therapies in oncology and immunology.
2 minutes to read